Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Epigenetics of lung cancer: a translational perspective.

Quintanal-Villalonga Á, Molina-Pinelo S.

Cell Oncol (Dordr). 2019 Aug 8. doi: 10.1007/s13402-019-00465-9. [Epub ahead of print] Review.

PMID:
31396859
2.

Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry.

Marrugal Á, Ferrer I, Pastor MD, Ojeda L, Quintanal-Villalonga Á, Carnero A, Molina-Pinelo S, Paz-Ares L.

Cells. 2019 Jul 31;8(8). pii: E806. doi: 10.3390/cells8080806.

3.

A patent review of FGFR4 selective inhibition in cancer (2007-2018).

Quintanal-Villalonga A, Ferrer I, Molina-Pinelo S, Paz-Ares L.

Expert Opin Ther Pat. 2019 May 30;29(6):429-438. doi: 10.1080/13543776.2019.1624720. Print 2019 Jun. Review.

PMID:
31146605
4.

FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective.

Quintanal-Villalonga A, Molina-Pinelo S, Yagüe P, Marrugal Á, Ojeda-Márquez L, Suarez R, Ponce-Aix S, Enguita AB, Carnero A, Ferrer I, Paz-Ares L.

Lung Cancer. 2019 May;131:112-121. doi: 10.1016/j.lungcan.2019.02.007. Epub 2019 Feb 8.

PMID:
31027687
5.

FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy.

Quintanal-Villalonga A, Molina-Pinelo S, Cirauqui C, Ojeda-Márquez L, Marrugal Á, Suarez R, Conde E, Ponce-Aix S, Enguita AB, Carnero A, Ferrer I, Paz-Ares L.

J Thorac Oncol. 2019 Apr;14(4):641-655. doi: 10.1016/j.jtho.2018.12.021. Epub 2019 Jan 9.

6.

Long non-coding RNAs as monitoring tools and therapeutic targets in breast cancer.

Pecero ML, Salvador-Bofill J, Molina-Pinelo S.

Cell Oncol (Dordr). 2019 Feb;42(1):1-12. doi: 10.1007/s13402-018-0412-6. Epub 2018 Oct 25. Review.

PMID:
30361825
7.

MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma.

Ferrer I, Quintanal-Villalonga Á, Molina-Pinelo S, Garcia-Heredia JM, Perez M, Suárez R, Ponce-Aix S, Paz-Ares L, Carnero A.

J Exp Clin Cancer Res. 2018 Aug 17;37(1):195. doi: 10.1186/s13046-018-0871-7.

8.

Corrigendum to "Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications".

Quintanal-Villalonga A, Paz-Ares L, Ferrer I, Molina-Pinelo S.

Dis Markers. 2018 Jul 19;2018:3714684. doi: 10.1155/2018/3714684. eCollection 2018.

9.

Corrigendum to "Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer".

Marrugal Á, Ojeda L, Paz-Ares L, Molina-Pinelo S, Ferrer I.

Dis Markers. 2018 Jul 8;2018:1404780. doi: 10.1155/2018/1404780. eCollection 2018.

10.

Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer.

Quintanal-Villalonga Á, Mediano M, Ferrer I, Meléndez R, Carranza-Carranza A, Suárez R, Carnero A, Molina-Pinelo S, Paz-Ares L.

Oncotarget. 2018 Apr 13;9(28):19945-19960. doi: 10.18632/oncotarget.24977. eCollection 2018 Apr 13.

11.

The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction.

Quintanal-Villalonga Á, Ojeda-Márquez L, Marrugal Á, Yagüe P, Ponce-Aix S, Salinas A, Carnero A, Ferrer I, Molina-Pinelo S, Paz-Ares L.

Sci Rep. 2018 Feb 5;8(1):2394. doi: 10.1038/s41598-018-20570-3.

12.

Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma.

Garrigós C, Espinosa M, Salinas A, Osman I, Medina R, Taron M, Molina-Pinelo S, Duran I.

Oncotarget. 2017 Nov 20;8(63):106551-106564. doi: 10.18632/oncotarget.22533. eCollection 2017 Dec 5.

13.

Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer.

Verdugo-Sivianes EM, Navas L, Molina-Pinelo S, Ferrer I, Quintanal-Villalonga A, Peinado J, Garcia-Heredia JM, Felipe-Abrio B, Muñoz-Galvan S, Marin JJ, Montuenga L, Paz-Ares L, Carnero A.

Oncotarget. 2017 Oct 26;8(62):105196-105210. doi: 10.18632/oncotarget.22111. eCollection 2017 Dec 1.

14.

Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement.

Quintanal-Villalonga Á, Carranza-Carranza A, Meléndez R, Ferrer I, Molina-Pinelo S, Paz-Ares L.

Clin Lung Cancer. 2017 Nov;18(6):667-674.e1. doi: 10.1016/j.cllc.2017.05.008. Epub 2017 May 10.

15.

Biological therapies in nonsmall cell lung cancer.

Zugazagoitia J, Molina-Pinelo S, Lopez-Rios F, Paz-Ares L.

Eur Respir J. 2017 Mar 2;49(3). pii: 1601520. doi: 10.1183/13993003.01520-2016. Print 2017 Mar. Review.

16.

Numb-like (NumbL) downregulation increases tumorigenicity, cancer stem cell-like properties and resistance to chemotherapy.

García-Heredia JM, Verdugo Sivianes EM, Lucena-Cacace A, Molina-Pinelo S, Carnero A.

Oncotarget. 2016 Sep 27;7(39):63611-63628. doi: 10.18632/oncotarget.11553.

17.

Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications.

Quintanal-Villalonga A, Paz-Ares L, Ferrer I, Molina-Pinelo S.

Dis Markers. 2016;2016:9214056. doi: 10.1155/2016/9214056. Epub 2016 Jul 26. Review. Erratum in: Dis Markers. 2018 Jul 19;2018:3714684.

18.

IL-11 and CCL-1: Novel Protein Diagnostic Biomarkers of Lung Adenocarcinoma in Bronchoalveolar Lavage Fluid (BALF).

Pastor MD, Nogal A, Molina-Pinelo S, Quintanal-Villalonga Á, Meléndez R, Ferrer I, Romero-Romero B, De Miguel MJ, López-Campos JL, Corral J, García-Carboner R, Carnero A, Paz-Ares L.

J Thorac Oncol. 2016 Dec;11(12):2183-2192. doi: 10.1016/j.jtho.2016.07.026. Epub 2016 Aug 12.

19.

Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.

Usó M, Jantus-Lewintre E, Bremnes RM, Calabuig S, Blasco A, Pastor E, Borreda I, Molina-Pinelo S, Paz-Ares L, Guijarro R, Martorell M, Forteza J, Camps C, Sirera R.

Oncotarget. 2016 Aug 16;7(33):52849-52861. doi: 10.18632/oncotarget.10811.

20.

Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer.

Marrugal Á, Ojeda L, Paz-Ares L, Molina-Pinelo S, Ferrer I.

Dis Markers. 2016;2016:2138627. doi: 10.1155/2016/2138627. Epub 2016 Jun 30. Review. Erratum in: Dis Markers. 2018 Jul 8;2018:1404780.

21.

Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer.

Molina-Pinelo S, Salinas A, Moreno-Mata N, Ferrer I, Suarez R, Andrés-León E, Rodríguez-Paredes M, Gutekunst J, Jantus-Lewintre E, Camps C, Carnero A, Paz-Ares L.

Oncotarget. 2016 Jul 15;9(4):4395-4410. doi: 10.18632/oncotarget.10611. eCollection 2018 Jan 12.

22.

Current Challenges in Cancer Treatment.

Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L.

Clin Ther. 2016 Jul;38(7):1551-66. doi: 10.1016/j.clinthera.2016.03.026. Epub 2016 May 2. Review.

PMID:
27158009
23.

Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer.

Estevez-Garcia P, Rivera F, Molina-Pinelo S, Benavent M, Gómez J, Limón ML, Pastor MD, Martinez-Perez J, Paz-Ares L, Carnero A, Garcia-Carbonero R.

Oncotarget. 2015 Mar 20;6(8):6151-9.

24.

MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer.

Molina-Pinelo S, Carnero A, Rivera F, Estevez-Garcia P, Bozada JM, Limon ML, Benavent M, Gomez J, Pastor MD, Chaves M, Suarez R, Paz-Ares L, de la Portilla F, Carranza-Carranza A, Sevilla I, Vicioso L, Garcia-Carbonero R.

BMC Cancer. 2014 Sep 7;14:656. doi: 10.1186/1471-2407-14-656.

25.

MicroRNA clusters: dysregulation in lung adenocarcinoma and COPD.

Molina-Pinelo S, Pastor MD, Suarez R, Romero-Romero B, González De la Peña M, Salinas A, García-Carbonero R, De Miguel MJ, Rodríguez-Panadero F, Carnero A, Paz-Ares L.

Eur Respir J. 2014 Jun;43(6):1740-9. doi: 10.1183/09031936.00091513. Epub 2014 Apr 17.

26.

MicroRNA-dependent regulation of transcription in non-small cell lung cancer.

Molina-Pinelo S, Gutiérrez G, Pastor MD, Hergueta M, Moreno-Bueno G, García-Carbonero R, Nogal A, Suárez R, Salinas A, Pozo-Rodríguez F, Lopez-Rios F, Agulló-Ortuño MT, Ferrer I, Perpiñá A, Palacios J, Carnero A, Paz-Ares L.

PLoS One. 2014 Mar 13;9(3):e90524. doi: 10.1371/journal.pone.0090524. eCollection 2014.

27.

VeriStrat: a prognostic and/or predictive biomarker for advanced lung cancer patients?

Molina-Pinelo S, Pastor MD, Paz-Ares L.

Expert Rev Respir Med. 2014 Feb;8(1):1-4. doi: 10.1586/17476348.2014.861744. Epub 2013 Dec 3.

PMID:
24308656
28.

Spinophilin loss correlates with poor patient prognosis in advanced stages of colon carcinoma.

Estevez-Garcia P, Lopez-Calderero I, Molina-Pinelo S, Muñoz-Galvan S, Salinas A, Gomez-Izquierdo L, Lucena-Cacace A, Felipe-Abrio B, Paz-Ares L, Garcia-Carbonero R, Carnero A.

Clin Cancer Res. 2013 Jul 15;19(14):3925-35. doi: 10.1158/1078-0432.CCR-13-0057. Epub 2013 May 31.

29.

Identification of proteomic signatures associated with lung cancer and COPD.

Pastor MD, Nogal A, Molina-Pinelo S, Meléndez R, Salinas A, González De la Peña M, Martín-Juan J, Corral J, García-Carbonero R, Carnero A, Paz-Ares L.

J Proteomics. 2013 Aug 26;89:227-37. doi: 10.1016/j.jprot.2013.04.037. Epub 2013 May 9.

PMID:
23665002
30.

Proteomic biomarkers in lung cancer.

Pastor MD, Nogal A, Molina-Pinelo S, Carnero A, Paz-Ares L.

Clin Transl Oncol. 2013 Sep;15(9):671-82. doi: 10.1007/s12094-013-1034-0. Epub 2013 Apr 20. Review.

PMID:
23606351
31.

Identification of oxidative stress related proteins as biomarkers for lung cancer and chronic obstructive pulmonary disease in bronchoalveolar lavage.

Pastor MD, Nogal A, Molina-Pinelo S, Meléndez R, Romero-Romero B, Mediano MD, López-Campos JL, García-Carbonero R, Sanchez-Gastaldo A, Carnero A, Paz-Ares L.

Int J Mol Sci. 2013 Feb 6;14(2):3440-55. doi: 10.3390/ijms14023440.

32.

PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome.

Estevez-Garcia P, Castaño A, Martin AC, Lopez-Rios F, Iglesias J, Muñoz-Galván S, Lopez-Calderero I, Molina-Pinelo S, Pastor MD, Carnero A, Paz-Ares L, Garcia-Carbonero R.

BMC Cancer. 2012 Nov 12;12:514. doi: 10.1186/1471-2407-12-514.

33.

Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies.

Molina-Pinelo S, Suárez R, Pastor MD, Nogal A, Márquez-Martín E, Martín-Juan J, Carnero A, Paz-Ares L.

Dis Markers. 2012;32(4):221-30. doi: 10.3233/DMA-2011-0882.

34.

Down-regulation of spinophilin in lung tumours contributes to tumourigenesis.

Molina-Pinelo S, Ferrer I, Blanco-Aparicio C, Peregrino S, Pastor MD, Alvarez-Vega J, Suarez R, Verge M, Marin JJ, Hernandez-Losa J, Ramon y Cajal S, Paz-Ares L, Carnero A.

J Pathol. 2011 Sep;225(1):73-82. doi: 10.1002/path.2905. Epub 2011 May 19.

PMID:
21598252
35.

Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation.

Molina-Pinelo S, Vallejo A, Díaz L, Soriano-Sarabia N, Ferrando-Martínez S, Resino S, Muñoz-Fernández MA, Leal M.

J Antimicrob Chemother. 2009 Sep;64(3):579-88. doi: 10.1093/jac/dkp248. Epub 2009 Jul 16.

PMID:
19608579
36.

HCV RNA in peripheral blood cell subsets in HCV-HIV coinfected patients at the end of PegIFN/RBV treatment is associated with virologic relapse.

de Felipe B, Leal M, Soriano-Sarabia N, Gutiérrez A, López-Cortés L, Molina-Pinelo S, Vallejo A.

J Viral Hepat. 2009 Jan;16(1):21-7. doi: 10.1111/j.1365-2893.2008.01043.x. Epub 2008 Aug 28.

PMID:
18761604
37.

Immunovirologic characteristics of human immunodeficiency virus-infected patients consisting mainly of injecting drug users on highly active antiretroviral treatment with prolonged virologic failure.

Vallejo A, Ruiz-Mateos E, Molina-Pinelo S, Soriano-Sarabia N, de Felipe B, Gutierrez S, Sánchez-Quijano A, Lissen E, Leal M.

Viral Immunol. 2006 Winter;19(4):759-67.

PMID:
17201671
38.

HIV-hepatitis C virus co-infection is associated with decreased plasmatic IL-7 levels.

Soriano-Sarabia N, Vallejo A, Molina-Pinelo S, Genebat M, del Mar Rodríguez M, Sánchez-Quijano A, Martínez-Moya M, Vivancos J, Leal M.

AIDS. 2007 Jan 11;21(2):253-5.

PMID:
17197823
39.

Thymic volume predicts CD4 T-cell decline in HIV-infected adults under prolonged treatment interruption.

Molina-Pinelo S, Vivancos J, De Felipe B, Soriano-Sarabia N, Valladares A, De la Rosa R, Vallejo A, Leal M.

J Acquir Immune Defic Syndr. 2006 Jun;42(2):203-6.

PMID:
16760798
40.

Thymic function-related markers within the thymus and peripheral blood: Are they comparable?

Arellano MV, Ordóñez A, Ruiz-Mateos E, Leal-Noval SR, Molina-Pinelo S, Hernández A, Vallejo A, Hinojosa R, Leal M.

J Clin Immunol. 2006 Jan;26(1):96-100.

PMID:
16418807
41.

Effect of hepatitis C virus coinfection on humoral immune alterations in naïve HIV-infected adults on HAART: a three year follow-up study.

Soriano-Sarabia N, Leal M, Delgado C, Molina-Pinelo S, De Felipe B, Ruiz-Mateos E, Sánchez-Quijano A, Lissen E, Vallejo A.

J Clin Immunol. 2005 May;25(3):296-302.

PMID:
15981096
42.

Prevalence and factors involved in discordant responses to highly active antiretroviral treatment in a closely followed cohort of treatment-naïve HIV-infected patients.

Molina-Pinelo S, Leal M, Soriano-Sarabia N, Gutiérrez S, Fernandez G, Muñoz-Fernández MA, Lissen E, Vallejo A.

J Clin Virol. 2005 Jun;33(2):110-115.

PMID:
15952251
43.

Analysis of quasispecies in the viral 5' untranslated region of hepatitis C virus to evaluate ribavirin mutagenic effect in patients receiving ribavirin and interferon-alfa.

Vallejo A, Molina-Pinelo S, Abad MA, Gómez G, Leal M, Sánchez-Quijano A, Lissen E.

Eur J Clin Microbiol Infect Dis. 2004 Dec;23(12):923-6.

PMID:
15599656

Supplemental Content

Loading ...
Support Center